AngioDynamics - ANGO Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" ANGO shares.
View ANGO analyst ratings or view top-rated stocks.

1 brokers have issued 12 month target prices for AngioDynamics' shares. Their ANGO share price forecasts range from $27.00 to $35.00. On average, they expect the company's stock price to reach $31.00 in the next year. This suggests a possible upside of 51.5% from the stock's current price.
View analysts price targets for ANGO or view top-rated stocks among Wall Street analysts.

AngioDynamics' stock was trading at $27.58 at the beginning of 2022. Since then, ANGO stock has decreased by 25.8% and is now trading at $20.46.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 6th 2022.
View our ANGO earnings forecast.

AngioDynamics will be holding an earnings conference call on Thursday, October 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13732702".

AngioDynamics, Inc. (NASDAQ:ANGO) released its quarterly earnings results on Tuesday, July, 12th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. The medical instruments supplier had revenue of $87 million for the quarter, compared to analyst estimates of $82.91 million. AngioDynamics had a negative net margin of 8.40% and a negative trailing twelve-month return on equity of 0.04%. The business's revenue was up 13.3% compared to the same quarter last year.

AngioDynamics issued an update on its FY 2023 earnings guidance on Tuesday, August, 2nd. The company provided earnings per share guidance of $0.01-$0.06 for the period, compared to the consensus earnings per share estimate of $0.08. The company issued revenue guidance of $342.00 million-$348.00 million, compared to the consensus revenue estimate of $337.70 million.

34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANGO stock can currently be purchased for approximately $20.46.

AngioDynamics (NASDAQ:ANGO) has a market capitalization of $800.19 million and generates $316.22 million in revenue each year. The medical instruments supplier earns $-26,550,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

The company employs 800 workers across the globe.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The official website for the company is www.angiodynamics.com. The medical instruments supplier can be reached via phone at (518) 795-1400, via email at mpolyviou@evcgroup.com, or via fax at 518-795-1401.